X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ALEMBIC PHARMA AJANTA PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 28.6 28.3 100.8% View Chart
P/BV x 11.8 6.5 182.1% View Chart
Dividend Yield % 0.5 0.7 70.0%  

Financials

 AJANTA PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ALEMBIC PHARMA
Mar-16
AJANTA PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720792 217.3%   
Low Rs1,103443 249.0%   
Sales per share (Unadj.) Rs194.6167.0 116.5%  
Earnings per share (Unadj.) Rs45.238.2 118.5%  
Cash flow per share (Unadj.) Rs50.342.0 119.8%  
Dividends per share (Unadj.) Rs8.004.00 200.0%  
Dividend yield (eoy) %0.60.6 87.5%  
Book value per share (Unadj.) Rs132.084.9 155.5%  
Shares outstanding (eoy) m88.77188.52 47.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.7 196.2%   
Avg P/E ratio x31.216.2 193.0%  
P/CF ratio (eoy) x28.114.7 190.9%  
Price / Book Value ratio x10.77.3 147.0%  
Dividend payout %17.710.5 168.8%   
Avg Mkt Cap Rs m125,299116,383 107.7%   
No. of employees `000NANA-   
Total wages/salary Rs m2,5704,214 61.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,27531,487 54.9%  
Other income Rs m16655 301.8%   
Total revenues Rs m17,44231,542 55.3%   
Gross profit Rs m5,80710,060 57.7%  
Depreciation Rs m451722 62.4%   
Interest Rs m4937 132.9%   
Profit before tax Rs m5,4749,356 58.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4602,160 67.6%   
Profit after tax Rs m4,0147,194 55.8%  
Gross profit margin %33.631.9 105.2%  
Effective tax rate %26.723.1 115.5%   
Net profit margin %23.222.8 101.7%  
BALANCE SHEET DATA
Current assets Rs m7,63915,066 50.7%   
Current liabilities Rs m2,7157,674 35.4%   
Net working cap to sales %28.523.5 121.4%  
Current ratio x2.82.0 143.3%  
Inventory Days Days4367 64.6%  
Debtors Days Days7941 193.6%  
Net fixed assets Rs m6,9148,237 83.9%   
Share capital Rs m177377 46.9%   
"Free" reserves Rs m11,44215,416 74.2%   
Net worth Rs m11,72116,005 73.2%   
Long term debt Rs m1490-   
Total assets Rs m14,81424,594 60.2%  
Interest coverage x112.9255.2 44.2%   
Debt to equity ratio x00-  
Sales to assets ratio x1.21.3 91.1%   
Return on assets %27.429.4 93.3%  
Return on equity %34.244.9 76.2%  
Return on capital %46.558.7 79.3%  
Exports to sales %55.155.7 98.9%   
Imports to sales %6.010.4 57.6%   
Exports (fob) Rs m9,52717,551 54.3%   
Imports (cif) Rs m1,0383,283 31.6%   
Fx inflow Rs m10,42217,811 58.5%   
Fx outflow Rs m1,6785,318 31.6%   
Net fx Rs m8,74412,493 70.0%   
CASH FLOW
From Operations Rs m3,2649,304 35.1%  
From Investments Rs m-2,093-3,105 67.4%  
From Financial Activity Rs m-1,186-1,959 60.5%  
Net Cashflow Rs m-154,240 -0.3%  

Share Holding

Indian Promoters % 73.8 74.1 99.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.9 53.4%  
FIIs % 7.6 9.1 83.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 13.9 122.3%  
Shareholders   20,968 49,328 42.5%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 23, 2018 11:11 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS